Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma

Mi Na Kim; Beom Kyung Kim; Yun Ho Roh; Na Ryung Choi; Su Jong Yu; Seung Up Kim

doi:10.1016/j.cgh.2022.02.014

Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma

Clin Gastroenterol Hepatol. 2022 Aug;20(8):1877-1880.e3. doi: 10.1016/j.cgh.2022.02.014. Epub 2022 Feb 15.

Authors

Mi Na Kim¹, Beom Kyung Kim², Yun Ho Roh³, Na Ryung Choi⁴, Su Jong Yu⁵, Seung Up Kim⁶

Affiliations

¹ Division of Gastroenterology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea.
² Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Liver Center, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.
³ Biostatistics Collaboration Unit, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.
⁴ Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
⁵ Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address: ydoctor2@snu.ac.kr.
⁶ Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea; Yonsei Liver Center, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea. Electronic address: ksukorea@yuhs.ac.

PMID: 35181566
DOI: 10.1016/j.cgh.2022.02.014

Abstract

Suppression of hepatitis B virus (HBV) replication with antiviral therapy (AVT) using nucleos(t)ide analogs reduces the risk of hepatocellular carcinoma (HCC) recurrence and prolongs survival after curative treatment.^1-5 Studies of the association between timing of AVT initiation and prognosis of patients with HCC receiving curative treatment are scarce. In the present study, we compared the therapeutic benefit of AVT, commenced before vs after curative treatment of HBV-related HCC, on long-term prognosis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / therapeutic use
Carcinoma, Hepatocellular* / pathology
Hepatitis B virus
Hepatitis B, Chronic* / complications
Hepatitis B, Chronic* / drug therapy
Humans
Liver Neoplasms* / pathology
Prognosis

Substances

Antiviral Agents